WEKO3
アイテム
Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy
http://hdl.handle.net/10295/00006177
http://hdl.handle.net/10295/00006177847323bc-6e92-4d0b-bdd8-b6fe074d2c6e
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
iA_2022_42.pdf (537.9 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2023-02-19 | |||||
| タイトル | ||||||
| タイトル | Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 主題 | ||||||
| 主題Scheme | Other | |||||
| 主題 | androgen deprivation therapy | |||||
| 主題 | ||||||
| 主題Scheme | Other | |||||
| 主題 | conditional survival | |||||
| 主題 | ||||||
| 主題Scheme | Other | |||||
| 主題 | metastatic hormone-naive | |||||
| 主題 | ||||||
| 主題Scheme | Other | |||||
| 主題 | net survival | |||||
| 主題 | ||||||
| 主題Scheme | Other | |||||
| 主題 | prostate cancer | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | open access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
| 作成者 |
Narita, Shintaro
× Narita, Shintaro× Nomura, Kyoko× Hatakeyama, Shingo× Takahashi, Masahiro× Sakurai, Toshihiko× Kawamura, Sadafumi× Hoshi, Senji× Ishida, Masanori× Kawaguchi, Toshiaki× Ishidoya, Shigeto× Shimoda, Jiro× Sato, Hiromi× Mitsuzuka, Koji× Tochigi, Tatsuo× Tsuchiya, Norihiko× Ohyama, Chikara× Arai, Yoichi× Nagashima, Kengo× Habuchi, Tomonori |
|||||
| 内容記述 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Background The purpose of this study was to identify predictive factors associated with conditional net survival in patients with metastatic hormone-naive prostate cancer (mHNPC) initially treated with androgen deprivation therapy (ADT). Methods At nine hospitals in Tohoku, Japan, the medical records of 605 consecutive patients with mHNPC who initially received ADT were retrospectively reviewed. The Pohar Perme estimator was used to calculate conditional net cancer-specific survival (CSS) and overall survival (OS) for up to 5 years subsequent to the diagnosis. Using multiple imputation, proportional hazard ratios for conditional CSS and OS were calculated with adjusted Cox regression models. Results During a median follow up of 2.95 years, 208 patients died, of which 169 died due to progressive prostate cancer. At baseline, the 5-year CSS and OS rates were 65.5% and 58.2%, respectively. Conditional 5-year net CSS and OS survival gradually increased for all the patients. In patients given a 5-year survivorship, the conditional 5-year net CSS and OS rates improved to 0.906 and 0.811, respectively. Only the extent of disease score (EOD) >= 2 remained a prognostic factor for CSS and OS up to 5 years; as survival time increased, other variables were no longer independent prognostic factors. Conclusions The conditional 5-year net CSS and OS in patients with mHNPC gradually increased; thus, the risk of mortality decreased with increasing survival. The patient's risk profile changed over time. EOD remained an independent prognostic factor for CSS and OS after 5-year follow-up. Conditional net survival can play a role in clinical decision-making, providing intriguing information for cancer survivors. | |||||
| 言語 | en | |||||
| 出版タイプ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| 書誌情報 |
en : Cancer Medicine 巻 8, 号 15, p. 6566-6577, 発行日 2019 |
|||||
| 収録物識別子 | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 2045-7634 | |||||
| 出版者 | ||||||
| 出版者 | John Wiley and Sons Inc | |||||
| 関連情報 | ||||||
| 関連タイプ | isIdenticalTo | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | https://doi.org/10.1002/cam4.2502 | |||||
| 権利情報 | ||||||
| 権利情報 | This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. | |||||
